CYGT yields 666666.67% · ABBV yields 3.06%● Live data
📍 CYGT pulled ahead of the other in Year 1
Combined, CYGT + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of CYGT + ABBV for your $10,000?
Cygnus eTransaction Group, Inc. operates as a transaction driven company that processes sales and payments for its customers' wholesale and retail sales, and distribution channels. The company provides ticketing, reservation, and event management solutions on a fee per transaction basis for theme parks, attractions, live entertainment venues, sporting events, and resorts. It offers smart client online sales engines; electronic, print at home, and delivery of tickets to consumers; virtual inventory distribution for third party sales channels; online sales of merchandise, lodging, rentals, ground transportation, shows, and events; self service ticketing systems with electronic will-call; and on-property box office management systems. Cygnus eTransaction Group also provides complimentary products and services, including access control, stored value cards, payment processing, management tools, real-time reporting, and Web analytics. In addition, the company offers a cePay payment processing system that allows its leisure customers and financial processing customers to obtain credit card, debit card, and e-check payment processing through a consolidated payment solution. cePay is implemented utilizing a plug 'n' play virtual terminal or a proprietary application programming interface. Cygnus eTransaction Group is headquartered in Lake Mary, Florida.
Full CYGT Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.